



DIAGNOS Provides an Update on Stock Warrants

BROSSARD, Quebec, Canada – October 6, 2026 - Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, provides an update on the stock warrants that were exercised and that have expired in the last two months (the “Period”), as well as the outstanding balance.

During the Period, 3,218,333 stock warrants were exercised for gross proceeds of \$1,287,333.

During the Period, the following stock warrants have expired.

Number of warrants	Issue date	Original expiry date	Amended expiry date
1,414,286	February 27, 2024	August 27, 2025	August 5, 2026
650,000	March 22, 2024	September 22, 2025	August 5, 2026
1,125,000	May 9, 2024	November 9, 2025	August 5, 2026
3,502,931	June 5, 2024	December 5, 2025	August 5, 2026
8,333,333	September 20, 2024	March 20, 2026	September 5, 2026
2,655,691	October 25, 2024	April 25, 2026	September 25, 2026

As at the date of this press release, the following stock warrants are outstanding and can be exercised at the price of \$0.40 per common share.

Number of warrants	Issue date	Original expiry date	Amended expiry date
6,715,369	February 5, 2025	August 5, 2026	June 5, 2027
13,494,459	December 5, 2025	June 5, 2027	n/a
513,248	December 5, 2025	June 5, 2027	n/a

DIAGNOS would like to thank the shareholders for their continuous support.

The currency stated in this press release is the Canadian dollar.

About DIAGNOS

DIAGNOS is a public Canadian corporation dedicated to the early detection of critical eye-related health problems. DIAGNOS manufactures CARA System, a software platform which assists health specialists in the detection of retinal eye pathologies. CARA System is currently licensed for commercialization in Canada and Saudi Arabia. By developing innovative products based on AI technologies, DIAGNOS' solutions provide healthcare clinicians with valuable information that refines diagnostic accuracy, streamlines workflows, and improves patient outcomes.

Additional information is available at www.dignos.com and www.sedarplus.com.

For further information, please contact:

Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca

This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.